Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
Alexis Maillard, Rabah Redjoul, Marion Klémencie, Hélène Labussière Wallet, Amandine Le Bourgeois, Maud D’Aveni, Anne Huynh, Ana Berceanu, Tony Marchand, Sylvain Chantepie, Carmen Botella Garcia, Michaël Loschi, Magalie Joris, Cristina Castilla‐Llorente, Anne Thiebaut‐Bertrand, Sylvie François, Mathieu Leclerc, Patrice Chevallier, Stéphanie Nguyen
Abstract
Three reports address the protection of the vulnerable population of patients with hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest that some patients who fail to mount a B-cell response to vaccine may nevertheless have protective T cell responses. As a group, these reports suggest that patients should continue to be immunized with additional doses to attempt to improve immune response but that they need to maintain the precautions recommended for the unvaccinated.